-
11.发明申请公开(公告)号：US20190389797A1
公开(公告)日：2019-12-26
申请号：US16553718
申请日：2019-08-28
发明人： Shriprakash Dhar Dwivedi , Ramesh Chandra Singh , Rajendra Gokalbhai Chavda , Jagdish Maganlal Patel , Daya Ram Pal , Pranav Jitendra Gangwar , Vikas Patel , Vishwadeepak Rama Pati Tripathi
IPC分类号： C07D207/333 , C07D207/32
摘要： The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.
-
公开(公告)号：US09879011B2
公开(公告)日：2018-01-30
申请号：US14384567
申请日：2013-03-12
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Kuldeep Natwarlal Jain , Kumar Kamlesh Singh , Jitendra Maganbhai Gajera
IPC分类号： C07D473/04 , C07D473/06
CPC分类号： C07D473/04 , C07D473/06 , Y10T428/2982
摘要： The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.
-
13.发明申请公开(公告)号：US20170144968A1
公开(公告)日：2017-05-25
申请号：US15366229
申请日：2016-12-01
发明人： Shriprakash Dhar Dwivedi , Ramesh Chandra Singh , Rajendra Gokalbhai Chavda , Jagdish Maganlal Patel , Daya Ram Pal , Pranav Jitendra Gangwar , Vikas Patel , Vishwadeepak Rama Pati Tripathi
IPC分类号： C07D207/333
CPC分类号： C07D207/333 , A61K31/402 , C07D207/32 , C07D207/325
摘要： The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.
-
公开(公告)号：US09650344B2
公开(公告)日：2017-05-16
申请号：US15168880
申请日：2016-05-31
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Mukul Hariprasad Sharma , Piyush Rajendra Sharma , Jayprakash Ajitsingh Parihar
CPC分类号： C07D223/16 , B65B7/02 , B65B31/00 , B65B61/20 , B65D31/02 , B65D31/04 , B65D81/266 , C07B2200/13 , C30B7/02 , C30B29/54 , Y10T428/2982
摘要： Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
-
公开(公告)号：US09439903B2
公开(公告)日：2016-09-13
申请号：US14059971
申请日：2013-10-22
发明人： Shriprakash Dhar Dwivedi , Kumar Kamlesh Singh , Ganpant Dan Shimbu Charan , Chetan Jayantibhai Vasava
IPC分类号： A61K31/506 , A61K45/06 , C07D403/00
CPC分类号： A61K31/506 , A61K45/06 , A61K2300/00
摘要： The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.
摘要翻译： 本发明的领域涉及制备无定形伊马替尼甲磺酸盐的方法。 特别地，本发明涉及制备稳定的无定形伊马替尼甲磺酸盐的方法。 更具体地，本发明涉及药物组合物，其包含稳定的无定形伊马替尼琥珀酸酯及其赋形剂。
-
公开(公告)号：US09840469B2
公开(公告)日：2017-12-12
申请号：US15485409
申请日：2017-04-12
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Mukul Hariprasad Sharma , Piyush Rajendra Sharma , Jayprakash Ajitsingh Parihar
IPC分类号： C07D223/16 , C30B7/02 , C30B29/54 , B65D30/08 , B65D81/26 , B65B31/00 , B65B7/02 , B65B61/20
CPC分类号： C07D223/16 , B65B7/02 , B65B31/00 , B65B61/20 , B65D31/02 , B65D31/04 , B65D81/266 , C07B2200/13 , C30B7/02 , C30B29/54 , Y10T428/2982
摘要： Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
-
公开(公告)号：US09249134B2
公开(公告)日：2016-02-02
申请号：US14223862
申请日：2014-03-24
IPC分类号： C07D417/14 , C07D417/12
CPC分类号： C07D417/12 , C07D417/14
摘要： A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 ° C. or 60% at 25 ° C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I).
摘要翻译： 式（I）的稳定的无定形形式的达沙替尼，其中在40℃下暴露于相对湿度为75％或在25℃下60％，在至少三个月的时间内无定形的达沙替尼不会改变为结晶 形式和制备式（I）的达沙替尼的无定形形式的方法。
-
18.发明授权Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof 有权制备甲磺酸达比加群酯及其中间体的多晶型物的方法公开(公告)号：US09212166B2
公开(公告)日：2015-12-15
申请号：US14373163
申请日：2013-01-21
IPC分类号： C07D401/12 , C07D213/75
CPC分类号： C07D401/12 , C07D213/75 , Y10T428/2982
摘要： The present invention provides crystalline form of intermediates of Formula 2A, The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.
摘要翻译： 本发明提供式2A中间体的结晶形式。本发明还提供制备甲磺酸达比加群酯的方法。 其中间体的多晶型物; 特别是制备中间体结晶形式的方法。 本发明还涉及结晶中间体用于制备甲磺酸达比加群酯的用途。
-
公开(公告)号：US20140323471A1
公开(公告)日：2014-10-30
申请号：US14358025
申请日：2012-11-12
发明人： Shriprakash Dhar Dwivedi , Ashok Prasad , Mukul Hariprasad Sharma , Piyush Rajendra Sharma , Jaiprakash Ajitsingh Parihar
IPC分类号： C07D223/16
CPC分类号： C07D223/16 , B65B7/02 , B65B31/00 , B65B61/20 , B65D31/02 , B65D31/04 , B65D81/266 , C07B2200/13 , C30B7/02 , C30B29/54 , Y10T428/2982
摘要： Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
摘要翻译： 公开了稳定的晶型II和盐酸伊伐布雷定的稳定晶型III及其制备方法。
-
20.发明授权Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof 有权匹伐他汀及其药学上可接受的盐的制备方法公开(公告)号：US08829186B2
公开(公告)日：2014-09-09
申请号：US13665932
申请日：2012-11-01
IPC分类号： C07D215/14
CPC分类号： C07D215/14
摘要： The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
摘要翻译： 本发明公开了一种化合物，其是匹伐他汀的碱金属或碱土金属盐，其中碱金属或地球金属包含镁，锌，钾，锶和钡中的一种或多种。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.013 秒)
